KROS Keros Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KROS

Price (delayed)

$57.83

Market cap

$2.08B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.2

Enterprise value

$1.76B

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros ...

Highlights
KROS's equity is up by 20% year-on-year and by 12% since the previous quarter
The company's net income fell by 46% YoY and by 7% QoQ
KROS's EPS is down by 25% year-on-year and by 4.8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kerostx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KROS
Market
Shares outstanding
35.98M
Market cap
$2.08B
Enterprise value
$1.76B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.22
Price to sales (P/S)
11,277.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11,675.23
Earnings
Revenue
$151,000
EBIT
-$152.99M
EBITDA
-$150.63M
Free cash flow
-$126.97M
Per share
EPS
-$5.2
Free cash flow per share
-$4.31
Book value per share
$11.09
Revenue per share
$0.01
TBVPS
$12.57
Balance sheet
Total assets
$370.03M
Total liabilities
$37.81M
Debt
$14.44M
Equity
$332.21M
Working capital
$322.92M
Liquidity
Debt to equity
0.04
Current ratio
14.25
Quick ratio
13.64
Net debt/EBITDA
2.11
Margins
EBITDA margin
-99,751.7%
Gross margin
100%
Net margin
-101,319.2%
Operating margin
-112,543.7%
Efficiency
Return on assets
-42.6%
Return on equity
-46.7%
Return on invested capital
-495.4%
Return on capital employed
-44.3%
Return on sales
-101,319.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KROS stock price

How has the Keros Therapeutics stock price performed over time
Intraday
6.72%
1 week
-0.77%
1 month
-12.52%
1 year
32.97%
YTD
45.45%
QTD
-12.64%

Financial performance

How have Keros Therapeutics's revenue and profit performed over time
Revenue
$151,000
Gross profit
$151,000
Operating income
-$169.94M
Net income
-$152.99M
Gross margin
100%
Net margin
-101,319.2%
The net margin has soared by 94% from the previous quarter
The operating margin has surged by 94% since the previous quarter
Keros Therapeutics's operating income has decreased by 48% YoY and by 9% from the previous quarter
The company's net income fell by 46% YoY and by 7% QoQ

Growth

What is Keros Therapeutics's growth rate over time

Valuation

What is Keros Therapeutics stock price valuation
P/E
N/A
P/B
5.22
P/S
11,277.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11,675.23
KROS's EPS is down by 25% year-on-year and by 4.8% since the previous quarter
The price to book (P/B) is 40% higher than the last 4 quarters average of 3.5
KROS's equity is up by 20% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Keros Therapeutics business performance
KROS's return on sales has surged by 94% since the previous quarter
The ROIC has soared by 84% YoY but it has contracted by 3.4% from the previous quarter
The ROE has contracted by 6% YoY and by 2.9% from the previous quarter
The company's return on assets fell by 3.9% YoY and by 2.7% QoQ

Dividends

What is KROS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KROS.

Financial health

How did Keros Therapeutics financials performed over time
The total liabilities is up by 29% year-on-year and by 24% since the previous quarter
The company's current ratio fell by 22% QoQ and by 17% YoY
The debt is 96% less than the equity
KROS's equity is up by 20% year-on-year and by 12% since the previous quarter
KROS's debt to equity is down by 20% since the previous quarter and by 20% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.